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Introduction
Imatinib mesylate (IM, also known as STI571, Glivec or 
Gleevec) is a competitive tyrosine kinase inhibitor com-
monly used for treatment of chronic myeloid leukemia 
(CML). It has also proven eﬃ   cient for the treatment of 
advanced gastrointestinal stromal tumors (GISTs), c-KIT 
mastocytosis and myeloproliferative disorders with re-
arrangement of the platelet derived growth factor recep-
tor (PDGFR) gene. In CML, IM inhibits the tyrosine 
kinase activity of the fusion protein of breakpoint cluster 
region (BCR) gene and the ABL tyrosine kinase (BCR-
ABL), which results from a t(9;22)(q34,q11) translocation 
known as the Philadelphia chromosome; this fusion 
protein has a role in leukemogenesis [1]. IM occupies the 
ATP-binding pocket of the ABL kinase domain; this 
prevents a change in conformation of the protein that 
would otherwise convert the molecule to its active form, 
and IM binding thereby leads to the apoptosis of target 
cells.
Th  ree main criteria can be used to evaluate the 
response to CML treatment: complete hematological 
remis sion,  deﬁ  ned as a normal peripheral blood count 
with normal spleen; complete cytogenetic response 
(CCyR), deﬁ  ned by absence of the Philadelphia chromo-
some in bone marrow metaphase analysis; and major 
molecular response (MMR), deﬁ   ned by the thousand-
fold (3 log) reduction in BCR-ABL transcript levels 
relative to the standardized baseline [1]. Other levels of 
cytogenetic or molecular response can be used [1], as 
mentioned in Table 1. Despite outstanding results of IM 
in the treatment of chronic phase CML, some patients do 
not achieve response criteria (for example, about 25% of 
patients did not achieve CCyR at 18 months [2], and 
some patients (about 25%) who initially responded well 
subsequently acquired resistance [3]. Apart from dosage 
errors, drug interactions and non-compliance with 
treatment, several mechanisms can contribute to the 
development of resistance: changes to the target protein 
(occurring through mutations or BCR-ABL ampliﬁ  ca-
tion); downstream BCR-ABL-independent pathways; and 
drug pharmacokinetics parameters (absorption, distri-
bution, metabolism and excretion). In malignancies other 
than CML, IM inhibits the tyrosine kinase domains of 
KIT and PDGFRα/β. Myeloproliferative disorders with 
PDGFR rearrangement show great sensitivity to IM and 
mostly require a lower dose of IM; this is especially true 
of chronic eosinophilic leukemia, which involves a fusion 
transcript of FIP1-like1 and PDGFRA [4]. In masto-
cytosis, the overall response rate varies according to 
c-KIT mutational status and has been reported to be 18 
to 36% [5]. In GISTs, IM leads to a response rate of 50 to 
70%, with a 2-year overall survival rate of 70% [6].
In the conventional dose range, a fourfold inter-patient 
variability has been reported both in the systemic 
exposure for a given dose and in the dose required to 
achieve a speciﬁ   c target level [7]. Variation in drug 
concentration may result in excessive toxicity or sub-
optimal anticancer eﬀ  ect. Reduced IM eﬃ   cacy has been 
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© 2010 BioMed Central LtdTable 1. Summary of studies of the effi   cacy of IM treatment in relation to pharmacokinetic genetic variants*
Genes SNP*
Base 
substitution†
Functional 
eff  ect‡ No of patients  Response criteria IM dosage Association References
ABCB1 rs1128503 C1236T + 90 French MMR at 12 months 400 mg in front line or 
2nd line after IFN
Higher MMR with 
1236T allele
[20]
- 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
87 English MMR¶ at 18 months 400 mg No [24]
46 Dutch Cumulative incidence 
of MMR and CMR at 12 
months
800 mg Higher MMR and CMR 
with CC genotype
[22]
557 French MMR at 12 months 400 mg; 400 mg + 
IFN 400 mg + AraC; 
600 mg
No [21]
52 Chinese CCyR at 12 months 400 mg Lower CCyR with TT 
genotype
[23]
rs2032582 G2677T/A + 90 French MMR at 12 months 400 mg in front line or 
2nd line after IFN
Lower MMR with 
2677G allele
[20]
- 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
46 Dutch Cumulative incidence 
of MMR and CMR at 12 
months
800 mg Lower CMR with TT 
genotype
[22]
557 French MMR at 12 months 400 mg; 400 mg + 
IFN 400 mg + AraC; 
600 mg
Higher MMR with 
2677G allele in the arm 
400 mg + AraC
[21]
52 Chinese CCyR at 12 months 400 mg Higher CCyR with AG/
AT/AA genotypes
[23]
rs1045642 C3435T¥ - 90 French MMR at 12 months 400 mg in front line or 
2nd line after IFN
No [20]
- 62 Japanese MMR ≥400 and ≤300 mg No [26]
ABCB1 rs1045642 C3435T¥ 229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg Overall survival lower 
with TT genotype 
but not confi  rmed in 
multivariate analysis
[25]
46 Dutch Cumulative incidence 
of MMR and CMR at 12 
months
800 mg Lower CMR with TT 
genotype
[22]
557 French MMR at 12 months 400 mg; 400 mg + 
IFN 400 mg + AraC; 
600 mg
No [21]
52 Chinese CCyR at 12 months 400 mg Higher CCyR with CC 
genotype
[23]
ABCG2 rs717620 - 62 Japanese MMR ≥400 and ≤300 mg No [26]
rs2231142 C421A¥ + 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg Higher CMR with 
AA genotype; more 
frequent need for IM 
dose escalation for CC 
genotype
[25]
rs2231137 G34A 229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg Lower MCyR and CCyR 
with GG genotypes
[25]
SLC22A1 rs12208357 32 Austrian MMR at 18 months 400 mg No [52]
- 132 English MMR 400 mg No [37]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
Continued overleaf
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of IM are neutropenia, superﬁ  cial edema, nausea, muscle 
cramps and rashes [1-3]. Trough IM plasma levels (Cmin) 
have been reported to be associated with MMR in CML 
patients following standard drug dose [8,9] A plasma 
threshold of 1,002  ng/ml had the best sensitivity and 
speciﬁ  city to predict MMR [8]. Patients with Cmin below 
this threshold have less chance to achieve MMR com-
pared with patients with Cmin above it. Likewise, higher 
circulating levels of IM correlated with a better response 
rate and with a longer time to progression in patients 
with advanced GISTs with Cmin of more than 1,100 ng/ml 
[10].
Observed inter-patient pharmacokinetic variability 
may be due to patients’ genetics. Polymorphisms in genes 
related to IM absorption, distribution, metabolism and 
excretion may aﬀ   ect the drug’s bioavailability and 
consequently the response to the drug. Th  e oral bio-
availability of IM depends on its gastrointestinal absorp-
tion and on how much of it survives the extensive ﬁ  rst 
pass metabolism that it encounters. Approximately 95% 
of IM in the human body is bound to plasma proteins, 
Table 1. Continued
Genes SNP*
Base 
substitution†
Functional 
eff  ect‡ No of patients  Response criteria IM dosage Association References
- 136 Australian MMR at 2 years <600 mg or ≥600 mg No [38]
rs2282143 - 132 English MMR 400 mg No [37]
- 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
rs34130495 G1201A¥ - 132 English MMR 400 mg Higher MMR with GA 
genotypes
[37]
SLC22A1 - 136 Australian MMR at 2 years <600 mg or ≥600mg No [38]
rs622342 - 132 English MMR 400 mg No [37]
rs1867351 - 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
rs683369 C480G - 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg Higher risk of loss 
of response and 
treatment failure with 
GG genotypes
[25]
rs628031 A1222G - 62 Japanese MMR ≥400 and ≤300 mg Higher MMR with GG 
genotypes
[26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
- 136 Australian MMR at 2 years <600 mg or ≥600mg No [38]
rs 72552763 - 136 Australian MMR at 2 years <600 mg or ≥600mg No [38]
SLCO1B3 rs4149117 - 62 Japanese MMR ≥400 and ≤300 mg No [26]
CYP3A5 rs776746 A6986G - 62 Japanese MMR ≥400 and ≤300 mg No [26]
229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg Lower MCyR and CCyR 
with AA genotypes
[25]
265 Indian Hematological response 
(HR)
400 mg Lower HR with GG 
genotypes
[41]
rs28383468 229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
AGP rs3182041 229 Canadian CyR and MR at 1, 1.5, 2, 
3, 4 and 5 years§
400, 600 or 800 mg No [25]
*All patients were in chronic phase except for the study of Kim et al. [25], in which 203 patients were in chronic phase and 26 patients in accelerated phase or in 
blast crisis. †The base substitution and rs number taken from the National Centre for Biotechnology information SNP database [53] are indicated for polymorphisms 
positively associated with IM response. For the remaining SNPs for which no association was found, only the rs number is indicated. ‡Functional impact in vivo: 
association had been found between polymorphisms and transcript levels of candidate genes or with trough IM concentration. §CyR, cytogenetic response; MR, 
molecular response; the cumulative incidence of major cytogenetic response (MCyR), CCyR, MMR, complete molecular response (CMR), loss of response, treatment 
failure and overall survival was measured. ¶MMR in patients with CCyR. ¥Polymorphisms with demonstrated functional eff  ect in vitro.
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Removal of IM is mediated by the P glycoprotein (P-gp, 
also called ABCB1 or MDR1) and breast cancer resis-
tance protein (BCRP), and uptake is mediated by human 
organic cation transporter 1 (hOCT1). IM is mostly 
metabolized by the cytochrome P450 (CYP) proteins 
CYP3A4 and CYP3A5 [11]. Various studies have analyzed 
the polymorphisms in genes encoding these proteins in 
relation to IM pharmacokinetics and response, as 
detailed below and in Table 1.
Overview of pharmacogenetic studies
Pharmacokinetic determinants
Cancer cells have the ability to become resistant to 
multiple diﬀ  erent drugs known as the multi drug resis-
tance (MDR) phenomenon. Th  is is due, among other 
mechanisms, to increased transport of drugs out of the 
cell. Mahon et al. [12] showed that IM is a substrate of 
P-gp and could thus be aﬀ   ected by MDR. Th  is was 
conﬁ  rmed by the facts that CML patients who did not 
achieve a CCyR had higher levels of expression of ABCB1 
and that there was a correlation between BCR-ABL and 
ABCB1 transcript levels in these patients [13]. However, 
in GIST patients, the expression level of ABCB1 did not 
seem to impair the initial response to IM [14].
ABCB1 contains 28 exons and is located on chromo  some 
7q21.1. Th  e silent C3435T polymorphism (rs1045642) in 
exon 26 of ABCB1 was the ﬁ   rst poly  morphism to be 
described; it was reported to modify P-gp expression [15] 
(Table 1). Decreased substrate speciﬁ  city, lower levels of 
intestinal P-gp and reduced levels of ABCB1 mRNA in 
3435TT individuals were reported [15-17]. Consistent 
with this, increased bioavailability of some P-gp sub-
strates has been observed to be associated with the 
3435TT genotype in several studies, although conﬂ  icting 
reports have subsequently appeared showing higher or 
no correlation with ABCB1 expression or P-gp activity 
[18]. Th   e C3435T polymorphism is in linkage disequili-
brium with a silent C1236T polymorphism (rs1128503) 
in exon 12 and a non-synonymous substitution G2677T/A 
(rs2032582) in exon 21, which leads to an amino acid 
change of Ala893 to serine or threonine; this may also 
contribute to the observed functional eﬀ  ect of variation 
at the C3435T polymorphism or at associated haplotypes.
Gurney et al. [19] reported a higher IM clearance in 
CML and GIST patients with the TT genotype at each of 
three positions in the ABCB1 gene (positions 1236, 2677 
and 3435). Reduction in dose as a result of toxicity also 
tended to be less commonly needed in these individuals 
[19]. We and our colleagues [20] found a higher 
frequency of MMR in CML patients carrying the 1236T 
allele and in patients with non-G genotypes at position 
2677. However, we could not conﬁ  rm these results in a 
larger patient cohort [21]. Only in the subgroup of 
patients treated with both IM and cytarabine (also called 
AraC) was an association with the ABCB1 2677 poly-
morphism found, but, contrary to the initial ﬁ  nding [20], 
the presence of allele 2677G (GA or GG or GT) was 
associated with a higher rate of MMR [21]. Th  is  ﬁ  nding is 
surprising given that AraC is not a substrate of P-gp. Th  e 
result is nevertheless similar to that reported by Deenik 
et al. [22], who observed a lower probability of cumulative 
MMR for CML patients who were homozygous for the 
ABCB1 alleles 3435T and 2677T, as well as for those 
having at least one 1236T allele. Finally, Ni et al. [23] 
reported a higher resistance rate in homozygous ABCB1 
1236T patients and in those with at least one 3435T 
allele, whereas better CCyR was observed for patients 
with the AG/AT/AA genotype at position 2677. Th  ree 
other studies conducted with CML patients did not ﬁ  nd 
an association between ABCB1 polymorphisms and 
MMR [24-26].
BCRP, which, like P-gp, causes removal of IM, is 
encoded by the ABCG2 gene located on chromosome 
4q22. BCRP is expressed not only in hematopoietic stem 
cells but also in hepatic and intestinal epithelial cells, and 
this aﬀ  ects the bioavailability of IM [27]. Th   e SNPs G34A 
(rs2231137), which substitutes a valine for a methionine, 
and C421A (rs2231142), which substitutes a glutamine 
for a lysine, are the most frequent non-synonymous poly-
morphisms in ABCG2 across various populations 
(Table 1) [28]. Experiments in vitro using various drug 
substrates showed that the Gln141Lys substitution aﬀ  ects 
the transport eﬃ   ciency of BCRP and may result in altered 
pharmacokinetics and drug-resistance proﬁ  les  [28]. 
Human embryonic kidney cells transfected with the 
141Lys variant of BCRP showed greater IM accumulation 
in vitro [29]. Consistent with this, a lower IM clearance 
and a higher dose-adjusted IM trough concentration 
were found in CML patients with the 141Lys variant 
[26,30], whereas the 141Gln variant reduced the response 
to IM [25]. In addition, the 34GG genotype was asso-
ciated with a lower frequency of cytogenetic response 
[25], although the functional eﬀ  ect of this variant is less 
clear. In contrast to the reports on CML, pharmacokinetic 
IM parameters were not signiﬁ  cantly  diﬀ  erent  across 
genotypes of Gln141Lys polymorphism in patients with 
GISTs and KIT-positive soft tissue sarcoma [29].
Th  e hOCT1 protein, encoded by the  solute carrier 
family 22 gene (SLC22A1) on chromosome 6q26 [31], 
may also aﬀ   ect the response to IM by regulating its 
uptake. CML patients with low hOCT1 activity showed 
lower probability of achieving MMR [32], whereas those 
with high baseline level showed better survival and 
higher probability of achieving a cytogenetic or molecular 
response [24,33,34]. Given the important predictive role 
of SLC22A1 expression, some investigators have focused 
on gene variations that may aﬀ   ect hOCT1 function 
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Gly401Ser amino acid replacements resulting from the 
corresponding genetic polymorphisms were shown to 
aﬀ  ect the transport of hOCT1 substrates [30]. Bazeos et 
al. [37] identiﬁ  ed an association between Gly401Ser sub-
sti  tution (G1201A, rs34130495) and the transcription 
level of the SLC22A1 gene (Table 1). In addition, CML 
patients with the 1201GA genotype had higher proba-
bility of achieving MMR than patients with the 1201GG 
genotype. Th   ese results, however, need to be conﬁ  rmed 
in a larger cohort given the low frequency of the A allele. 
Indeed, White et al. [38] were not able to replicate this 
ﬁ  nding. Kim et al. [25] showed instead that the SLC22A1 
C480G polymorphism (rs683369), which leads to 
Leu160Phe replacement, is associated with IM response 
in CML. Patients with the 480GG genotype showed a 
higher risk of treatment failure or loss of response than 
other genotypes. Finally, Takahashi et al. [26] showed 
that the SLC22A1 A1222G polymorphism (rs628031), 
which leads to Met408Val replacement, is associated with 
molecular response in the group of patients treated with 
IM doses lower than 400 mg. Patients with the 1222GG 
genotype showed a higher MMR rate.
Uptake of imatinib has also been described, in vitro, to 
be mediated to a modest extent by SLCO1B3, which 
encodes the organic anion-transporting polypeptide 1B3 
[39], but Takahashi et al. [26] did not ﬁ  nd any association 
with IM response (Table 1).
Metabolizing enzymes
Among CYP3A5 polymorphisms, the CYP3A5*3 allele 
is particularly interesting, as it appears with a 
suﬃ   ciently high frequency and has a clear functional 
role. Th  e CYP3A5*3 allele is deﬁ   ned by the A6986G 
substitution (rs776746), which generates a cryptic splice 
site and the introduction of a premature stop codon 
[40]. Individuals who are homozygous for this allele 
have reduced CYP3A5 levels and reduced metabolic 
capacity. In the study of Kim et al. [25], the 6986AA 
genotype had an adverse impact on achievement of 
CCyR, whereas Takahashi et al. [26] did not ﬁ  nd an 
association between this allele and dose-adjusted IM 
trough concentration or clinical response (Table 1). In 
contrast, Sailaja et al. [41] found a higher frequency of 
the 6986GG genotype in CML patients with a minor or 
poor hematological response.
Binding proteins
Th   e role of AGP in the mechanisms of IM resistance is 
not yet clear [42]. In GIST patients, an association was 
found between high plasma AGP levels and a lower 
clearance of IM and its metabolite [43]. Kim et al. [25] 
did not observe any association between AGP 
polymorphisms and IM response in CML patients.
Pharmacodynamic determinants
IM tyrosine kinase targets represent potential pharma  co-
dynamic determinants. Any modiﬁ  cation in these targets 
could modulate the eﬃ     cacy of IM and aﬀ  ect  its 
mechanism of action.
Acquired point mutations in the tyrosine kinase 
domain of BCR-ABL are the most frequent mechanism 
of acquired resistance to IM in CML [44]. Th  ese 
mutations should be distinguished from the poly-
morphisms in the ABL gene that could be responsible for 
primary resistance. However, their role is not yet clear. 
For example, the Lys247Arg amino acid replacement 
resulting from an adenine-to-guanine substitution does 
not seem to be functional [45]. Ernst et al. [46] found six 
diﬀ  erent polymorphisms in CML patients with failure of 
treatment or suboptimal IM response, but the clinical 
impact of these variations still needs to be investigated.
Approximately 95% of GIST patients express the 
receptor tyrosine kinase KIT and 86% of GISTs contain 
c-KIT activating mutations that lead to a ligand-
independent activation of the tyrosine kinase. Th  ese 
somatic mutations mostly occur in the juxtamembrane 
domain (encoded by exon 11) and extracellular domains 
(exon 9). Th   e target kinase mutations in exon 11 are asso-
ciated with a better overall partial response rate using 
standard Southwest oncology group response criteria [47].
Some GIST patients without c-KIT mutations show 
alterations in the juxtamembrane domain (encoded by 
exon 12) or activation loop domain (exon 18) of 
PDGFRA, with those with exon 18 mutations having a 
poor response to IM [47]. Resistance due to the somatic 
mutations in the tyrosine kinase domain of PDGFRA has 
also been described in a few cases of chronic eosinophilic 
leukemia [48]. IM-associated edema is believed to involve 
a disruption of PDGF signaling. Th  e role of PDGFR 
polymorphisms in the risk of developing severe edema 
during IM treatment from CML was analyzed by Bruck 
et al. [49], but no signiﬁ  cant association was found.
Dressman  et al. [50] analyzed the eﬀ   ect of 68 
polymorphisms in 26 genes on the cytogenetic response 
to IM. Th   ey found a signiﬁ  cant association between the 
rs2290573 polymorphism located in an intron of a 
putative tyrosine kinase gene, DKFZP434C131, and the 
major cytogenetic response (MCyR) in a subset of IM-
treated patients. Patients homozygous for the C allele had 
a signiﬁ   cantly lower MCyR rate and a higher risk of 
disease progression than patients with other genotypes. 
It is unknown whether this polymorphism has a func-
tional eﬀ  ect or whether it is a genetic marker in linkage 
disequilibrium with another polymorphism that is 
functional.
A substantial proportion of patients with IM resistance 
do not have BCR-ABL tyrosine kinase domain mutations, 
suggesting the involvement of additional mechanisms in 
Dulucq and Krajinovic Genome Medicine 2010, 2:85 
http://genomemedicine.com/content/2/11/85
Page 5 of 8IM resistance. Activation of other signaling pathways 
when IM blocks the BCR-ABL-mediated pathway might 
facilitate cell death avoidance in CML [51]. Recently, Kim 
et al. [51] analyzed a variety of polymorphisms in the 
genes of the apoptosis, angiogenesis, cell growth, Wilms 
tumor gene or interferon (IFN) signaling pathways in 
CML patients. An association obtained both in test and 
validation cohorts is particularly interesting. Th  e CC 
genotype of the rs2069705 polymorphism in the IFNG 
(IFN-γ) gene was associated with a higher rate of 
molecular and cytogenetic response, suggesting a 
potential involvement of the IFN-γ signaling pathway in 
the mechanism of IM action in CML.
Clinical relevance of the pharmacogenetics of IM
Given that there is a large variability in response rate and 
IM systemic exposure following a standard drug dose, 
pharmacogenetic studies may provide insights into the 
role of genetic components in this variability. Focusing 
on a variety of genes whose products are essential for IM 
levels and action, these studies may identify potential 
pharmacokinetic and/or pharmacodynamic markers of 
IM response. Th  ese markers, complementing existing 
ones such as drug plasma concentrations, could allow the 
prediction, for each individual, of a lack of eﬃ   cacy or 
excess toxicity, leading ﬁ   rst to pharmacogenetically 
guided prospective clinical trials and ultimately to 
personalized treatment. Pharmacogenetic IM studies 
have been conducted so far mainly in patients diagnosed 
with CML or GIST, probably because of the higher 
incidence of these two diseases. Th  e  eﬃ   cacy and toxicity 
of IM seem to depend on both IM pharmacokinetics, 
inﬂ  uenced by several enzymes and transporters, and IM 
pharmacodynamics, inﬂ  uenced by mutational status of 
the target. Several polymorphisms aﬀ  ecting the pharma-
co  kinetic determinants of IM have been identiﬁ  ed. 
Nevertheless, the data are not yet suﬃ   ciently conclusive 
to translate into individual drug dose adjustment (several 
reasons for this are outlined below). Meanwhile, trough 
IM plasma levels could help physicians to deﬁ  ne the best 
IM dose [8]. In addition, the determination of hOCT1 
activity before initiation of IM therapy may also be 
helpful [38].
Concluding remarks
Despite several groups attempting to demonstrate the 
impact of candidate gene polymorphisms, conﬂ  icting 
results remain. Th  ese discrepancies could be explained, 
at least in some cases, by diﬀ   erent response criteria, 
study sample size, IM dosage and treatment protocols. 
Most studies have focused on ABCB1 polymorphisms, 
and constitutive or compensatory changes in expression 
of other ABC transporters, or IM-induced changes in 
ABCB1 expression, may confound the observed results in 
these studies. Th   e results are not always supported by the 
expected functional eﬀ  ect of a given polymorphism, and 
they still require replication. It will be necessary to target 
other genotypes beyond those already analyzed to more 
comprehensively estimate the eﬀ  ect of the genes from the 
analysis of both individual polymorphisms and 
haplotypes.
It seems clear that the eﬀ  ect of IM depends on several 
genes. An approach involving multiple candidate genes 
may thus give the beneﬁ   t of including the potential 
eﬀ  ects of gene-gene interactions, but this has not been 
much explored and usually requires larger studies. 
Further studies are clearly needed to elucidate the real 
impact of candidate gene polymorphisms on the IM 
response and to what extent the use of second generation 
tyrosine kinase inhibitors (nilotinib and dasatinib) may 
eventually overcome the resistance imposed by certain 
genetic variations.
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